Literature DB >> 32220011

eNOS rs2070744 polymorphism might influence predisposition to hemorrhagic cerebral vascular diseases in East Asians: A meta-analysis.

Qiuling Wang1, Hongri Sun2, Xiaoguang Qi3, Minfeng Zhou4.   

Abstract

INTRODUCTION: Endothelial nitric oxide synthase (eNOS) polymorphisms might influence predisposition to hemorrhagic cerebral vascular diseases, but the results of already published studies regarding relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases were still controversial.
METHODS: The authors performed this meta-analysis to estimate relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases in a larger pooled population by combing the results of already published related studies. The authors searched Pubmed, Embase, Web of Science, and CNKI for already published studies.
RESULTS: Eighteen already published studies were pooled analyzed in this meta-analysis. The pooled meta-analyses results showed that eNOS rs2070744 polymorphism was significantly associated with predisposition to hemorrhagic cerebral vascular diseases in East Asians (dominant comparison: OR = 0.77, p = .01; overdominant comparison: OR = 1.24, p = .04; allele comparison: OR = 0.78, p = .006) Nevertheless, the pooled meta-analyses did not reveal any positive results for eNOS rs1799983 and rs869109213 polymorphisms.
CONCLUSIONS: This meta-analysis suggested that eNOS rs2070744 polymorphism, but not rs1799983 and rs869109213 polymorphisms, might influence predisposition to hemorrhagic cerebral vascular diseases in East Asians.
© 2020 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.

Entities:  

Keywords:  East Asians; endothelial nitric oxide synthase (eNOS); gene polymorphisms; hemorrhagic cerebral vascular diseases; meta-analysis

Mesh:

Substances:

Year:  2020        PMID: 32220011      PMCID: PMC7218252          DOI: 10.1002/brb3.1538

Source DB:  PubMed          Journal:  Brain Behav            Impact factor:   2.708


INTRODUCTION

Hemorrhagic cerebral vascular disease, characterized by structural or functional abnormalities of cerebral vessels, and associated spontaneous bleeding into brain tissue, is one of the leading causes of death and disability all over the world (Global Burden of Disease Study 2013 Collaborators, 2015; Caceres & Goldstein, 2012). Although its definite etiologies and pathogenesis mechanisms are still unclear, accumulating evidence suggested that genetic architecture greatly influence its development. First, the incidences of hemorrhagic cerebral vascular diseases in different populations differed significantly (Backhaus et al., 2015; Krishnan et al., 2018), and genetic background was probably the underlying reason of this phenomenon. Second, previous association studies also detected numerous predisposing gene loci of hemorrhagic cerebral vascular diseases in different populations (Carpenter, Singh, Gandhi, & Prestigiacomo, 2016; Chen, Chang, & Chen, 2018). However, the etiologies and pathogenesis mechanisms of hemorrhagic cerebral vascular diseases are extremely sophisticated, and genetic factors that contribute to the development of hemorrhagic cerebral vascular diseases still need intensively explorations. Endothelial nitric oxide synthase (eNOS) is essential for maintaining vascular homeostasis and plays vital roles in modulating vascular endothelial function (Besler et al., 2011; Tsutsui, Shimokawa, Morishita, Nakashima, & Yanagihara, 2006). Therefore, if a polymorphism can impact gene expression or protein structure of eNOS, it is likely that this polymorphism might lead to severe vascular endothelial dysfunction and influence predisposition to hemorrhagic cerebral vascular diseases. In the last two decades, investigators across the world extensively explored relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases, especially for intracranial aneurysm (IA) and its associated aneurysmal subarachnoid hemorrhage (aSAH), yet the relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases is still controversial. Thus, we performed this meta‐analysis to get a more statistically reliable conclusion regarding relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases by pooling the results of already published relevant studies.

MATERIALS AND METHODS

The PRISMA guideline was followed by the authors when conducting this meta‐analysis (Moher, Liberati, Tetzlaff, Altman, & PRISMA group, 2009).

Literature search and inclusion criteria

Literature searching of Pubmed, Web of Science, Embase, and CNKI was performed by the authors using the following terms: (endothelial nitric oxide synthase or nitric oxide synthase type III or eNOS or NOS3) and (polymorphism or variant or variation or mutation or SNP or genome‐wide association study or genetic association study or genotype or allele) and (hemorrhagic cerebral vascular disease or hemorrhagic cerebrovascular disease or cerebral hemorrhage or basal ganglia hemorrhage or putaminal hemorrhage or subarachnoid hemorrhage or cerebrum hemorrhage or brain hemorrhage or intracranial hemorrhage or intracranial aneurysm or cerebral aneurysm). When searching CNKI, the authors translated searching terms into Chinese. The authors also checked the references of obtained articles manually for additional related studies. Eligible studies must meet all of three inclusion criteria: I. formally published case–control studies evaluating relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases; II. provide sufficient genotypic data of eNOS polymorphisms in patients with hemorrhagic cerebral vascular diseases and controls; III. the whole manuscript is available in English or Chinese. Articles were excluded when at least one of the following three conditions was fulfilled: I. studies not concerning eNOS polymorphisms and hemorrhagic cerebral vascular diseases; II. reviews or expert comments; III. case series only involved participants with hemorrhagic cerebral vascular diseases. When duplicate reports were observed during literature searching, only the most recent one was included for pooled meta‐analyses. The literature searching was performed by the first author and the second author, and the latest literature searching update was performed on 10 November 2019.

Data extraction and quality assessment

We extracted following items from included studies: I. surname of the first author; II. year of online publication; III. country and ethnicity of involved participants; IV. number of patients and controls; V. genotypic distributions of eNOS polymorphisms in patients and control subjects. We also calculated p values of Hardy–Weinberg equilibrium (HWE) based on genotypic distributions of eNOS polymorphisms using chi‐square test. The authors used Newcastle–Ottawa scale (NOS) to assess the quality of included studies (Stang, 2010). The NOS's score range is from zero to nine, and the methodology quality of an article was considered to be good when it got a score of more than seven. Data extraction and quality assessment of included studies were performed by the first author and the second author separately. The authors wrote to the corresponding authors for additional data when they failed to extract necessary information from included studies. In case of disagreement between the first author and the second author, the two authors would consult the corresponding author for suggestions, and a consensus must be reached among three authors.

Statistical analyses

The authors used Review Manager to pool meta‐analyses results (Version 5.3.3, The Cochrane Collaboration, Software Update). The authors calculated ORs and 95% CIs of Z test to evaluate relationship between eNOS polymorphisms and predisposition to hemorrhagic cerebral vascular diseases in dominant, recessive, overdominant, and allele models (Keat Wei, Griffiths, Irene, & Kooi, 2019; Wei, Griffiths, Kooi, & Irene, 2019). The authors set the statistical significant threshold at 0.05. The authors used I 2 statistics to estimate heterogeneity. I 2 values of 25%, 50%, and 75% represented low, moderate, and high heterogeneities, respectively. The authors used DerSimonian–Laird method (random‐effect model) to pool the results if I 2 is larger than 50%. Otherwise, the authors used Mantel–Haenszel method (fixed‐effect model) to pool the results. The authors also conducted subgroup analyses by ethnicity. The authors examined stabilities of pooled results through omitting one study each time and pooling the results of the other studies. The authors examined publication biases through funnel plots.

RESULTS

Characteristics of included studies

One hundred and sixty articles were retrieved by the authors through our literature searching strategy. The authors assessed thirty‐six articles for eligibility after omitting unrelated or repeated reports. Twelve reviews and six case series were further excluded by the authors. Totally eighteen studies were finally pooled in our meta‐analyses (Figure 1). Extracted data of eligible studies were summarized in Table 1.
Figure 1

Flowchart of study selection for this meta‐analysis

Table 1

The characteristics of included studies in this meta‐analysis

First author (year)CountryEthnicityType of diseaseSample sizeGenotype distribution p value for HWENOS score
CasesControls
rs1799983 G/TGG/GT/TT
Du (2014)ChinaEast AsianAneurysmal subarachnoid hemorrhage60/6027/19/1439/16/5.0977
Khurara (2004)USACaucasianAneurysmal subarachnoid hemorrhage51/9020/25/620/55/15.0327
Kim (2011)KoreaEast AsianIntracranial aneurysms149/121125/24/098/23/0.2488
Konar (2019)IndiaMixedAneurysmal subarachnoid hemorrhage100/10071/23/676/23/1.6077
Koshy (2008)IndiaMixedAneurysmal subarachnoid hemorrhage122/22485/35/2159/61/4.5018
Krex (2006)GermanyCaucasianIntracranial aneurysms142/19064/67/1196/76/18.6027
Krischek (2006)JapanEast AsianIntracranial aneurysms405/176349/50/6145/23/8<.0018
Liu (2013)ChinaEast AsianIntracranial aneurysms82/8249/25/836/38/8.6568
Ozum (2008)TurkeyCaucasianAneurysmal subarachnoid hemorrhage53/6026/23/434/22/4.8638
Staalsø (2014)DenmarkCaucasianAneurysmal subarachnoid hemorrhage331/498151/153/27233/216/49.9188
Xu (2009)ChinaEast AsianAneurysmal subarachnoid hemorrhage58/6727/17/1445/15/7.0057
Zhao (2008)ChinaEast AsianHypertensive intracerebral hemorrhage70/11253/15/2105/7/0.7327
Zhe (2019)ChinaEast AsianAneurysmal subarachnoid hemorrhage169/15690/50/29106/38/12.0038
rs2070744 T/CTT/TC/CC
Akagawa (2005 a)JapanEast AsianIntracranial aneurysms220/214176/41/3179/34/1.6488
Akagawa (2005 b)KoreaEast AsianIntracranial aneurysms191/191144/46/1149/41/1.3048
Deng (2018)ChinaEast AsianAneurysmal subarachnoid hemorrhage71/14270/1/0130/11/1.1777
Khurara (2003)USACaucasianAneurysmal subarachnoid hemorrhage52/9012/35/528/46/16.6997
Kim (2011)KoreaEast AsianIntracranial aneurysms149/121122/24/399/22/0.2718
Konar (2019)IndiaMixedAneurysmal subarachnoid hemorrhage100/10071/23/676/23/1.6077
Koshy (2008)IndiaMixedAneurysmal subarachnoid hemorrhage122/22468/51/3136/81/7.2198
Krex (2006)USACaucasianIntracranial aneurysms135/18448/60/2771/86/27.9087
Krischek (2006)JapanEast AsianIntracranial aneurysms405/176326/72/7145/23/8<.0018
Liu (2013)ChinaEast AsianIntracranial aneurysms82/8259/19/469/12/1.5698
Song (2006)KoreaEast AsianAneurysmal subarachnoid hemorrhage132/113106/26/0100/13/0.5167
Staalsø (2014)DenmarkCaucasianAneurysmal subarachnoid hemorrhage331/498145/147/39197/233/68.9468
Zhe (2019)ChinaEast AsianAneurysmal subarachnoid hemorrhage169/15682/60/2795/47/14.0298
rs869109213 VNTR4b4b/4b4a/4a4a
Bi (2010)ChinaEast AsianAneurysmal subarachnoid hemorrhage80/10759/18/391/16/1.7538
Fang (2011)ChinaEast AsianHypertensive intracerebral hemorrhage62/23652/10/0187/48/1.2577
Khurara (2004)USACaucasianAneurysmal subarachnoid hemorrhage51/9025/25/170/16/4.0297
Kim (2011)KoreaEast AsianIntracranial aneurysms149/121122/24/396/25/0.2058
Konar (2019)IndiaMixedAneurysmal subarachnoid hemorrhage100/10065/30/572/25/3.6487
Koshy (2008)IndiaMixedAneurysmal subarachnoid hemorrhage122/22477/40/5143/77/4.0778
Krex (2006)GermanyCaucasianIntracranial aneurysms142/18998/41/3126/55/8.5257
Krischek (2006)JapanEast AsianIntracranial aneurysms405/176325/70/10143/30/3.3418
Staalsø (2014)DenmarkCaucasianAneurysmal subarachnoid hemorrhage332/498254/71/7344/145/9.1558

Abbreviations: HWE, Hardy–Weinberg equilibrium; NA, not available; NOS, Newcastle–ottawa scale.

Flowchart of study selection for this meta‐analysis The characteristics of included studies in this meta‐analysis Abbreviations: HWE, Hardy–Weinberg equilibrium; NA, not available; NOS, Newcastle–ottawa scale.

Meta‐analyses of eNOS rs1799983 polymorphism and hemorrhagic cerebral vascular diseases

Thirteen studies involving 1792 cases and 1936 control subjects were eligible for estimation of relationship between eNOS rs1799983 polymorphism and hemorrhagic cerebral vascular diseases. The pooled meta‐analyses did not reveal any significant associations for eNOS rs1799983 polymorphism and hemorrhagic cerebral vascular diseases (see Table 2).
Table 2

Pooled meta‐analyses results of the current study

PolymorphismsPopulationSample sizeDominant comparisonRecessive comparisonOverdominant comparisonAllele comparison
p valueOR (95%CI) p valueOR (95%CI) p valueOR (95%CI) p valueOR (95%CI)
rs1799983 G/TOverall1792/1936.210.84 (0.64–1.10).331.26 (0.80–1.98).241.09 (0.94–1.27).140.83 (0.64–1.06)
Caucasian577/838.710.96 (0.78–1.19).260.81 (0.56–1.17).301.12 (0.90–1.39).821.02 (0.87–1.20)
East Asian993/774.200.71 (0.42–1.20).201.66 (0.76–3.61).551.13 (0.76–1.68).150.69 (0.42–1.14)
aSAH944/1255.100.77 (0.56–1.05).101.57 (0.92–2.70).241.11 (0.93–1.34).060.75 (0.55–1.01)
IA848/681.850.95 (0.55–1.64).320.77 (0.46–1.29).751.09 (0.65–1.83).890.97 (0.60–1.56)
rs2070744 T/COverall2159/2291.050.87 (0.76–1.00).471.10 (0.85–1.42).101.12 (0.98–1.29).060.90 (0.80–1.00)
Caucasian518/772.691.05 (0.83–1.32).710.94 (0.68–1.30).890.98 (0.79–1.23).641.04 (0.88–1.22)
East Asian1419/1195 .01 0.77 (0.63–0.94) .161.42 (0.87–2.32) .04 1.24 (1.01–1.52) .006 0.78 (0.66–0.93)
aSAH977/132.210.82 (0.59–1.12).861.03 (0.75–1.40).281.11 (0.92–1.33).270.85 (0.64–1.31)
IA1182/968.090.83 (0.67–1.03).301.27 (0.81–2.01).211.15 (0.93–1.42).060.84 (0.70–1.01)
rs869109213 VNTROverall1443/1741.490.90 (0.66–1.22).261.32 (0.81–2.14).651.08 (0.78–1.48).400.90 (0.70–1.15)
Caucasian525/777.620.82 (0.37–1.82).480.77 (0.37–1.61).531.34 (0.54–3.32).790.93 (0.53–1.63)
East Asian696/640.720.95 (0.71–1.27).122.19 (0.82–5.86).830.97 (0.72–1.31).390.89 (0.68–1.16)
aSAH685/1019.240.72 (0.41–1.25).211.48 (0.80–2.75).331.33 (0.74–2.40).190.75 (0.49–1.15)
IA758/722.531.09 (0.84–1.42).811.10 (0.50–2.41).490.91 (0.69–1.19).601.07 (0.84–1.35)

Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; CI, confidence interval; IA, intracranial aneurysm; OR, odds ratio.

The values in bold represent there is statistically significant differences between cases and controls.

Pooled meta‐analyses results of the current study Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; CI, confidence interval; IA, intracranial aneurysm; OR, odds ratio. The values in bold represent there is statistically significant differences between cases and controls.

Meta‐analyses of eNOS rs2070744 polymorphism and hemorrhagic cerebral vascular diseases

Twelve studies involving 2,159 cases and 2,291 control subjects were eligible for estimation of relationship between eNOS rs2070744 polymorphism and hemorrhagic cerebral vascular diseases. eNOS rs2070744 polymorphism was found to be significantly associated with hemorrhagic cerebral vascular diseases in East Asians (dominant comparison: OR = 0.77, 95% CI 0.63–0.94; overdominant comparison: OR = 1.24, 95% CI 1.01–1.52; allele comparison: OR = 0.78, 95% CI 0.66–0.93) (see Table 2).

Meta‐analyses of eNOS rs869109213 polymorphism and hemorrhagic cerebral vascular diseases

Nine studies involving 1,443 cases and 1741 control subjects were eligible for estimation of relationship between eNOS rs869109213 polymorphism and hemorrhagic cerebral vascular diseases. The pooled meta‐analyses did not reveal any significant associations for eNOS rs869109213 polymorphism and hemorrhagic cerebral vascular diseases (see Table 2).

Sensitivity analyses

Stabilities of pooled meta‐analyses results were examined by omitting one study each time and pooling the results of the other studies. The trends of associations remained unchanged in sensitivity analyses, indicating that our pooled meta‐analyses results were statistically stable.

Publication biases

Publication biases were examined by funnel plots. Funnel plots were overall symmetrical, suggesting that our pooled meta‐analyses results were not likely to be severely influenced by publication biases (Figure S1).

DISCUSSION

Endothelial nitric oxide synthase, which is primarily found in the vascular endothelium, can continuously generate NO, and thus, it is essential for maintaining basal vascular tone and normal cerebral blood flow, and its dysregulation has also been found to be closely related to vascular endothelial dysfunction (Rudic et al., 1998; Faraci & Brian 1994). Since vascular endothelial dysfunction is clearly implicated in vascular diseases, eNOS gene polymorphisms were also intensively studied regarding their relationship with predisposition to various types of cerebral vascular diseases. There were already abundant meta‐analyses regarding eNOS gene polymorphisms and ischemic cerebral vascular diseases (Shyu et al., 2017; Wei et al., 2017). So in this meta‐analysis, we focused on hemorrhagic cerebral vascular diseases. The pooled meta‐analyses results demonstrated that eNOS rs2070744 polymorphism might influence susceptibility to hemorrhagic cerebral vascular diseases in East Asians, but we failed to find any significant associations for eNOS rs1799983 and rs869109213 polymorphisms. The trends of associations remained unchanged in sensitivity analyses, suggesting that our pooled meta‐analyses results were quite statistically stable. Few points need to be considered when interpreting our findings. First, previous experimental studies demonstrated that all investigated polymorphisms were correlated with altered gene expression or protein structure of eNOS (AlFadhli, 2013; Dosenko, Zagoriy, Haytovich, Gordok, & Moibenko, 2006; Elakkad, Abou‐Aisha, Hassanein, & Gad, 2017). To be brief, the rs2070744 polymorphism is associated with a thymine to cytosine mutation at coden‐786 in the 5′‐flanking region of the eNOS gene, which can significantly reduce eNOS gene expression. The rs1799983 polymorphism is associated with a Glu‐to‐Asp change at nucleotide 298 in exon 7 that is demonstrated to be associated with a trend of reduction of eNOS enzyme activity, and rs869109213 polymorphism, which can result in a variable number of tandem repeats (27 bp VNTRs) in intron 4, is also associated with altered eNOS enzyme activity. Thus, it is likely that these eNOS variations might influence normal functioning of eNOS, lead to vascular endothelial dysfunction, and influence predisposition to hemorrhagic cerebral vascular diseases. In this meta‐analysis, only rs2070744 polymorphism was found to be significantly associated with predisposition to hemorrhagic cerebral vascular diseases. Nevertheless, we noticed that the trends of associations for rs1799983 and rs869109213 polymorphisms were actually similar to rs2070744 polymorphism. Therefore, maybe our pooled meta‐analyses were still not statistically sufficient to detect the real associations between eNOS polymorphisms and hemorrhagic cerebral vascular diseases, and future studies in larger populations are still needed so as to get a more statistically robust conclusion. Second, the etiologies and pathogenesis mechanisms of hemorrhagic cerebral vascular diseases are extremely sophisticated. In this meta‐analysis, we noticed that almost all eligible studies were about IA and its associated aSAH, whereas only a few studies were about hypertensive cerebral hemorrhage. Nevertheless, considering that the majority of hemorrhagic cerebral vascular diseases should be related to hypertensive disorders. Future studies should concentrate more on elucidating the relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases of other etiologies, particularly hypertension. Third, we aimed to analyze all eNOS polymorphisms at the beginning. However, we did not find sufficient eligible studies to support meta‐analyses of other eNOS polymorphisms, so we have to focus on only three polymorphisms in this meta‐analysis. Like all meta‐analyses, a few limitations of our pooled meta‐analyses have to be acknowledged. First, our pooled meta‐analyses results were derived from pooling unadjusted findings of eligible studies since the authors did not have raw data (Xie, Shi, & Liu, 2017). Second, environmental factors might also influence relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases. However, most investigators only focused on genetic associations in their works, so genetic–environmental interactions could not be explored in this meta‐analysis (Wang et al., 2018). Third, we did not consider gray literatures (data that are not formally published in scientific books or journals, which include working papers, theses and dissertations, market reports, government documents, and conference posters). Therefore, despite that funnel plots were overall symmetrical, we still could not rule out the possibility that our pooled results might be affected by potential publication biases (Suvatha et al., 2018). So to conclude, this meta‐analysis demonstrated that eNOS rs2070744 polymorphism might influence predisposition to hemorrhagic cerebral vascular diseases in East Asians. These results also suggested that eNOS might involve in the development of hemorrhagic cerebral vascular diseases, and it may serve as a potential therapeutic target for hemorrhagic cerebral vascular diseases.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

AUTHORS' CONTRIBUTIONS

Qiuling Wang and Minfeng Zhou designed this meta‐analysis. Qiuling Wang and Hongri Sun searched literatures. Xiaoguang Qi analyzed the data. Qiuling Wang and Minfeng Zhou wrote the manuscript. All authors approved the final manuscript as submitted.

ETHICAL APPROVAL

This article does not contain any studies with human participants or animals performed by any of the authors; thus, ethical approval is not required. Click here for additional data file.
  23 in total

1.  Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations.

Authors:  Victor E Dosenko; Vyacheslav Y Zagoriy; Nikolay V Haytovich; Olga A Gordok; Alexey A Moibenko
Journal:  Acta Biochim Pol       Date:  2006-05-30       Impact factor: 2.149

2.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.

Authors:  Christian Besler; Kathrin Heinrich; Lucia Rohrer; Carola Doerries; Meliana Riwanto; Diana M Shih; Angeliki Chroni; Keiko Yonekawa; Sokrates Stein; Nicola Schaefer; Maja Mueller; Alexander Akhmedov; Georgios Daniil; Costantina Manes; Christian Templin; Christophe Wyss; Willibald Maier; Felix C Tanner; Christian M Matter; Roberto Corti; Clement Furlong; Aldons J Lusis; Arnold von Eckardstein; Alan M Fogelman; Thomas F Lüscher; Ulf Landmesser
Journal:  J Clin Invest       Date:  2011-06-23       Impact factor: 14.808

Review 3.  The Roles of TLR Gene Polymorphisms in Atherosclerosis: A Systematic Review and Meta-Analysis of 35,317 Subjects.

Authors:  X Xie; X Shi; M Liu
Journal:  Scand J Immunol       Date:  2017-07       Impact factor: 3.487

Review 4.  Genetic risk factors for spontaneous intracerebral haemorrhage.

Authors:  Amanda M Carpenter; Inder P Singh; Chirag D Gandhi; Charles J Prestigiacomo
Journal:  Nat Rev Neurol       Date:  2015-12-16       Impact factor: 42.937

Review 5.  Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis.

Authors:  Loo Keat Wei; Anthony Au; Saras Menon; Lyn R Griffiths; Cheah Wee Kooi; Looi Irene; Jiangyang Zhao; Chaeyoung Lee; Avdonina Maria Alekseevna; Muhammad Radzi Abdul Hassan; Zariah Abdul Aziz
Journal:  J Stroke Cerebrovasc Dis       Date:  2017-07-29       Impact factor: 2.136

Review 6.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2015-06-07       Impact factor: 202.731

7.  Association of eNOS and Cav-1 gene polymorphisms with susceptibility risk of large artery atherosclerotic stroke.

Authors:  Hann-Yeh Shyu; Ming-Hua Chen; Yi-Hsien Hsieh; Jia-Ching Shieh; Ling-Rong Yen; Hsiao-Wei Wang; Chun-Wen Cheng
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

8.  Meta-Analysis of Factor V, Factor VII, Factor XII, and Factor XIII-A Gene Polymorphisms and Ischemic Stroke.

Authors:  Loo Keat Wei; Lyn R Griffiths; Cheah Wee Kooi; Looi Irene
Journal:  Medicina (Kaunas)       Date:  2019-04-11       Impact factor: 2.430

9.  Influence of endothelial nitric oxide synthase gene intron-4 27bp repeat polymorphism on its expression in autoimmune diseases.

Authors:  Suad AlFadhli
Journal:  Dis Markers       Date:  2013       Impact factor: 3.434

10.  eNOS rs2070744 polymorphism might influence predisposition to hemorrhagic cerebral vascular diseases in East Asians: A meta-analysis.

Authors:  Qiuling Wang; Hongri Sun; Xiaoguang Qi; Minfeng Zhou
Journal:  Brain Behav       Date:  2020-03-26       Impact factor: 2.708

View more
  2 in total

1.  eNOS rs2070744 polymorphism might influence predisposition to hemorrhagic cerebral vascular diseases in East Asians: A meta-analysis.

Authors:  Qiuling Wang; Hongri Sun; Xiaoguang Qi; Minfeng Zhou
Journal:  Brain Behav       Date:  2020-03-26       Impact factor: 2.708

2.  Identification of New Targets and the Virtual Screening of Lignans against Alzheimer's Disease.

Authors:  Mayara Dos Santos Maia; Gabriela Cristina Soares Rodrigues; Natália Ferreira de Sousa; Marcus Tullius Scotti; Luciana Scotti; Francisco Jaime B Mendonça-Junior
Journal:  Oxid Med Cell Longev       Date:  2020-08-15       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.